Pacific Udall Center researcher and collaborator publications include:



Chittoor-Vinod VG, Nichols RJ, Schüle B. Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism. Int J Mol Sci. 2021 Jan 21;22(3):1045. PMC7864502.

Zarifkar P, Kim J, La C, Zhang K, YorkWilliams S, Levine TF, Tian L, Borghammer P, Poston KL. Cognitive impairment in Parkinson’s disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ. Parkinsonism Relat Disord. 2021 Jan 12;83:71-78. PMID: 33484978

Ryman SG, Yutsis M, Tian L, Henderson VW, Montine TJ, Salmon DP, Galasko D, Poston KL “Cognition at each stage of Lewy body disease with co-occurring Alzheimer’s disease pathology” Journal of Alzheimer’s Disease 2020 (Accepted)

Martini DN, Morris R, Madhyastha TM, Grabowski TJ, Oakley J, Hu SC, Zabetian CP, Edwards KL, Hiller A, Chung K, Ramsey K, Lapidus JA, Cholerton B, Montine TJ, Quinn JF, Horak FB. Relationship between Sensorimotor Inhibition and Mobility in Older Adults with and without Parkinson’s Disease. J Gerontol A Biol Sci Med Sci. 2020 Nov 30:glaa300. PMID: 33252618.

Eis PS, Huang N, Langston JW, Hatchwell E, Schüle B. Loss-of-Function NUBPL Mutation May Link Parkinson’s Disease to Recessive Complex I Deficiency. Front Neurol. 2020 Oct 29;11:555961. PMC7667465.

Phongpreecha T, Fernandez R, Mrdjen D, Culos A, Gajera CR, Wawro AM, Stanley N, Gaudilliere B, Poston KL, Aghaeepour N, Montine TJ. Single-cell peripheral immunoprofiling of Alzheimer’s and Parkinson’s diseases. Sci Adv. 2020 Nov 25;6(48):eabd5575. PMC7688332.

Corces MR, Shcherbina A, Kundu S, Gloudemans MJ, Frésard L, Granja JM, Louie BH, Eulalio T, Shams S, Bagdatli ST, Mumbach MR, Liu B, Montine KS, Greenleaf WJ, Kundaje A, Montgomery SB, Chang HY, Montine TJ. Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer’s and Parkinson’s diseases. Nat Genet. 2020 Nov;52(11):1158-1168. PMC7606627.

Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, Scholler J, Montine TJ, Bhoj VG, Reddy R, Mohan S, Maillard I, Kriegstein AR, June CH, Chang HY, Posey AD Jr, Satpathy AT. Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell. 2020 Oct 1;183(1):126-142.e17. PMC7640763.

Rane S, Owen J, Hippe DS, Cholerton B, Zabetian CP, Montine T, Grabowski TJ. White Matter Lesions in Mild Cognitive Impairment and Idiopathic Parkinson’s Disease: Multimodal Advanced MRI and Cognitive Associations. J Neuroimaging. 2020 Nov;30(6):843-850. PMC7722040.

Linortner P, McDaniel C, Shahid M, Levine TF, Tian L, Cholerton B, Poston KL. White Matter Hyperintensities Related to Parkinson’s Disease Executive Function. Mov Disord Clin Pract. 2020 Apr 30;7(6):629-638. PMC7396844.

Gryc W, Roberts KA, Zabetian CP, Weintraub D, Trojanowski JQ, Quinn JF, Hiller AL, Chung KA, Poston KL, Yang L, Hu SC, Edwards KL, Montine TJ, Cholerton BA. Hallucinations and Development of Dementia in Parkinson’s Disease. J Parkinsons Dis. 2020;10(4):1643-1648. PMC7609584.

Sheng L, Stewart T, Yang D, Thorland E, Soltys D, Aro P, Khrisat T, Xie Z, Li N, Liu Z, Tian C, Bercow M, Matsumoto J, Zabetian CP, Peskind E, Quinn JF, Shi M, Zhang J. Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson’s disease pathogenesis. Acta Neuropathol Commun. 2020 Jul 8;8(1):102. PMC7346449.

Scharenberg SG, Poletto E, Lucot KL, Colella P, Sheikali A, Montine TJ, Porteus MH, Gomez-Ospina N. Engineering monocyte/macrophage-specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing. Nat Commun. 2020 Jul 3;11(1):3327. doi: 10.1038/s41467-020-17148-x. Erratum in: Nat Commun. 2020 Aug 20;11(1):4231. Abstract corrected. PMC7335164.

Wallen ZD, Appah M, Dean MN, Sesler CL, Factor SA, Molho E, Zabetian CP, Standaert DG, Payami H. Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. NPJ Parkinsons Dis. 2020 Jun 12;6:11. PMC7293233.

Rane S, Koh N, Oakley J, Caso C, Zabetian CP, Cholerton B, Montine TJ, Grabowski T. Arterial spin labeling detects perfusion patterns related to motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2020 Jul;76:21-28. PMC7554132.

Day TKM, Madhyastha TM, Askren MK, Boord P, Montine TJ, Grabowski TJ. Attention Network Test fMRI data for participants with Parkinson’s disease and healthy elderly. F1000Res. 2019 Jun 4;8:780. PMC7217223.

Wilson EN, Swarovski MS, Linortner P, Shahid M, Zuckerman AJ, Wang Q, Channappa D, Minhas PS, Mhatre SD, Plowey ED, Quinn JF, Zabetian CP, Tian L, Longo FM, Cholerton B, Montine TJ, Poston KL, Andreasson KI. Soluble TREM2 is elevated in Parkinson’s disease subgroups with increased CSF tau. Brain. 2020 Mar 1;143(3):932-943. PMC7089668.

Cholerton B, Poston KL, Tian L, Quinn JF, Chung KA, Hiller AL, Hu SC, Specketer K, Montine TJ, Edwards KL, Zabetian CP. Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson’s Disease. Mov Disord Clin Pract. 2019 Dec 14;7(1):61-69. PMC6962683.

Morris R, Martini DN, Smulders K, Kelly VE, Zabetian CP, Poston K, Hiller A, Chung KA, Yang L, Hu SC, Edwards KL, Cholerton B, Grabowski TJ, Montine TJ, Quinn JF, Horak F. Cognitive associations with comprehensive gait and static balance measures in Parkinson’s disease. Parkinsonism Relat Disord. 2019 Dec;69:104-110. PMC6900452.

Ryman SG, Poston KL. MRI biomarkers of motor and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2020 Apr;73:85-93. PMC7145760.

Young JI, Sivasankaran SK, Wang L, Ali A, Mehta A, Davis DA, Dykxhoorn DM, Petito CK, Beecham GW, Martin ER, Mash DC, Pericak-Vance M, Scott WK, Montine TJ, Vance JM. Genome-wide brain DNA methylation analysis suggests epigenetic reprogramming in Parkinson disease. Neurol Genet. 2019 Jun 24;5(4):e342. doi: 10.1212/NXG.0000000000000342. Erratum in: Neurol Genet. 2019 Aug 15;5(4):e355. PMC6659138.

Specketer K, Zabetian CP, Edwards KL, Tian L, Quinn JF, Peterson-Hiller AL, Chung KA, Hu SC, Montine TJ, Cholerton BA. Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinson’s disease. J Clin Exp Neuropsychol. 2019 Oct;41(8):803-813. PMC6681669.

Stewart T, Shi M, Mehrotra A, Aro P, Soltys D, Kerr KF, Zabetian CP, Peskind ER, Taylor P, Shaw LM, Trojanowski JQ, Zhang J; Alzheimer’s Disease Neuroimaging Initiative. Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. J Alzheimers Dis. 2019;69(1):263-276. PMC6513710.

Cholerton B, Omidpanah A, Verney SP, Nelson LA, Baker LD, Suchy-Dicey A, Longstreth WT Jr, Howard BV, Henderson JA, Montine TJ, Buchwald D. Type 2 diabetes and later cognitive function in older American Indians: The Strong Heart Study. Int J Geriatr Psychiatry. 2019 Jul;34(7):1050-1057. PMC6579638.

Cholerton B, Weiner MW, Nosheny RL, Poston KL, Mackin RS, Tian L, Ashford JW, Montine TJ. Cognitive Performance in Parkinson’s Disease in the Brain Health Registry. J Alzheimers Dis. 2019;68(3):1029-1038. PMC6497062.

Shahid M, Kim J, Leaver K, Hendershott T, Zhu D, Cholerton B, Henderson VW, Tian L, Poston KL. An increased rate of longitudinal cognitive decline is observed in Parkinson’s disease patients with low CSF Aß42 and an APOE ε4 allele. Neurobiol Dis. 2019 Jul;127:278-286. PMC6588475.

Morris R, Martini DN, Madhyastha T, Kelly VE, Grabowski TJ, Nutt J, Horak F. Overview of the cholinergic contribution to gait, balance and falls in Parkinson’s disease. Parkinsonism Relat Disord. 2019 Jun;63:20-30. PMC6682416.

Hendershott TR, Zhu D, Llanes S, Zabetian CP, Quinn J, Edwards KL, Leverenz JB, Montine T, Cholerton B, Poston KL. Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson’s disease. Mov Disord. 2019 Feb;34(2):285-291. PMC6532623.

Shi M, Sheng L, Stewart T, Zabetian CP, Zhang J. New windows into the brain: Central nervous system-derived extracellular vesicles in blood. Prog Neurobiol. 2019 Apr;175:96-106. PMC6546433.

Das T, Hwang JJ, Poston KL. Episodic recognition memory and the hippocampus in Parkinson’s disease: A review. Cortex. 2019 Apr;113:191-209. PMC6445686.

Kim HM, Nazor C, Zabetian CP, Quinn JF, Chung KA, Hiller AL, Hu SC, Leverenz JB, Montine TJ, Edwards KL, Cholerton B. Prediction of cognitive progression in Parkinson’s disease using three cognitive screening measures. Clin Park Relat Disord. 2019;1:91-97. PMC7197868.

Chen KT, Gong E, de Carvalho Macruz FB, Xu J, Boumis A, Khalighi M, Poston KL, Sha SJ, Greicius MD, Mormino E, Pauly JM, Srinivas S, Zaharchuk G. Ultra-Low-Dose 18F-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs. Radiology. 2019 Mar;290(3):649-656. Epub 2018 Dec 11. Erratum in: Radiology. 2020 Sep;296(3):E195. PMC6394782.

Foltynie T, Langston JW. Therapies to Slow, Stop, or Reverse Parkinson’s Disease. J Parkinsons Dis. 2018;8(s1):S115-S121. PMC6311371.

Gajera CR, Fernandez R, Postupna N, Montine KS, Fox EJ, Tebaykin D, Angelo M, Bendall SC, Keene CD, Montine TJ. Mass synaptometry: High-dimensional multi parametric assay for single synapses. J Neurosci Methods. 2019 Jan 15;312:73-83. PMC6363340.

Flanagan ME, Cholerton B, Latimer CS, Hemmy LS, Edland SD, Montine KS, White LR, Montine TJ. TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study. J Alzheimers Dis. 2018;66(4):1549-1558. PMC6382067.

Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D; IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. Detecting Mild Cognitive Deficits in Parkinson’s Disease: Comparison of Neuropsychological Tests. Mov Disord. 2018 Nov;33(11):1750-1759. PMC6261669.

Quansah E, Peelaerts W, Langston JW, Simon DK, Colca J, Brundin P. Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. Mol Neurodegener. 2018 May 24;13(1):28. PMC5968614.

Cholerton B, Johnson CO, Fish B, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Hu SC, Mata IF, Leverenz JB, Poston KL, Montine TJ, Zabetian CP, Edwards KL. Sex differences in progression to mild cognitive impairment and dementia in Parkinson’s disease. Parkinsonism Relat Disord. 2018 May;50:29-36. PMC5943177

Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, Nelson PT, Jicha GA, Woltjer R, Quinn JF, Kaye J, Leverenz JB, Tsuang D, Longfellow K, Yearout D, Kukull W, Keene CD, Montine TJ, Zabetian CP, Trojanowski JQ. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017 Jan;16(1):55-65. PMC5181646.

Mata IF, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Van Deerlin VM,Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Espay AJ, Revilla FJ, Devoto J, Yearout D, Hu SC, Cholerton BA, Montine TJ,Edwards KL, Zabetian CP. Large-scale exploratory genetic analysis of cognitiveimpairment in Parkinson’s disease. Neurobiol Aging. 2017 Aug;56:211.e1-211.e7. PMC5536182.

Cholerton B, Omidpanah A, Madhyastha TM, Grabowski TJ, Suchy-Dicey AM, Shibata DK, Nelson LA, Verney SP, Howard BV, Longstreth WT Jr, Montine TJ, Buchwald D. Total Brain and Hippocampal Volumes and Cognition in Older American Indians: The Strong Heart Study. Alzheimer Dis Assoc Disord. 2017 Apr-Jun;31(2):94-100. PMC5492994.

Postupna N, Latimer CS, Larson EB, Sherfield E, Paladin J, Shively CA, Jorgensen MJ, Andrews RN, Kaplan JR, Crane PK, Montine KS, Craft S, Keene CD, Montine TJ. Human Striatal Dopaminergic and Regional Serotonergic Synaptic Degeneration with Lewy Body Disease and Inheritance of APOE ε4. Am J Pathol. 2017 Apr;187(4):884-895. PMC5397713.

Wang S, Peterson DJ, Gatenby JC, Li W, Grabowski TJ, Madhyastha TM. Evaluation of Field Map and Nonlinear Registration Methods for Correction of Susceptibility Artifacts in Diffusion MRI. Front Neuroinform. 2017 Feb 21;11:17. PMC5318394.

Dublin S, Walker RL, Gray SL, Hubbard RA, Anderson ML, Yu O, Montine TJ, Crane PK, Sonnen JA, Larson EB. Use of Analgesics (Opioids and Nonsteroidal Anti-Inflammatory Drugs) and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. J Alzheimers Dis. 2017;58(2):435-448. PMC5594560.

Madhyastha TM, Koh N, Day TKM, Hernández-Fernández M, Kelley A, Peterson DJ, Rajan S, Woelfer KA, Wolf J, Grabowski TJ. Running Neuroimaging Applications on Amazon Web Services: How, When, and at What Cost? Front Neuroinform. 2017 Nov 3;11:63. PMC5675877.

Yang L, Stewart T, Shi M, Pottiez G, Dator R, Wu R, Aro P, Schuster RJ, Ginghina C, Pan C, Gao Y, Qian W, Zabetian CP, Hu SC, Quinn JF, Zhang J. An alpha-synuclein MRM assay with diagnostic potential for Parkinson’s disease and monitoring disease progression. Proteomics Clin Appl. 2017 Jul;11(7-8). PMC5540649

Corces MR, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, Satpathy AT, Rubin AJ, Montine KS, Wu B, Kathiria A, Cho SW, Mumbach MR, Carter AC, Kasowski M, Orloff LA, Risca VI, Kundaje A, Khavari PA, Montine TJ, Greenleaf WJ, Chang HY. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat Methods. 2017 Oct;14(10):959-962. PMC5623106

Lee A, Särkkä A, Madhyastha TM, Grabowski TJ. Characterizing cross-subject spatial interaction patterns in functional magnetic resonance imaging studies: A two-stage point-process model. Biom J. 2017 Nov;59(6):1352-1381. PMC5880034.

Licking N, Murchison C, Cholerton B, Zabetian CP, Hu SC, Montine TJ, Peterson-Hiller AL, Chung KA, Edwards K, Leverenz JB, Quinn JF. Homocysteine and cognitive function in Parkinson’s disease. Parkinsonism Relat Disord. 2017 Nov;44:1-5. PMC5858907

Boord P, Madhyastha TM, Askren MK, Grabowski TJ. Executive attention networks show altered relationship with default mode network in PD. Neuroimage Clin. 2016 Nov 5;13:1-8. PMC5121155.

Cholerton B, Larson EB, Quinn JF, Zabetian CP, Mata IF, Keene CD, Flanagan M, Crane PK, Grabowski TJ, Montine KS, Montine TJ. Precision Medicine: Clarity for the Complexity of Dementia. Am J Pathol 2016; 186:500-6. PMC4816691

Cook TJ, Hoekstra JG, Eaton DL, Zhang J. Mortalin is Expressed by Astrocytes and Decreased in the Midbrain of Parkinson’s Disease Patients. Brain Pathol. 2016 Jan;26(1):75-81. PMC4676952.

Cooper CA, Jain N, Gallagher MD, Weintraub D, Xie SX, Berlyand Y, Espay AJ, Quinn J, Edwards KL, Montine T, Van Deerlin VM, Trojanowski J, Zabetian CP, Chen-Plotkin AS. Common variant rs356182 near SNCA defines a Parkinson’s disease endophenotype. Ann Clin Transl Neurol. 2016 Nov 25;4(1):15-25. PMC5221454.

Costa-Mallen P, Zabetian CP, Hu SC, Agarwal P, Yearout D, Checkoway H. Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease. J Neural Transm (Vienna). 2016 Nov;123(11):1319-1330. PMC5096643.

Crane PK, Gibbons LE, Dams-O’Connor K, Trittschuh E, Leverenz JB, Keene CD, Sonnen J, Montine TJ, Bennett DA, Leurgans S, Schneider JA, Larson EB. Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings. JAMA Neurol. 2016 Sep 1;73(9):1062-9. PMC5319642.

Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Goldman JG, Stebbins GT, Bernard B, Wszolek ZK, Ross OA, Dickson DW, Eidelberg D, Mattis PJ, Niethammer M, Yearout D, Hu SC, Cholerton BA, Smith M, Mata IF, Montine TJ, Edwards KL, Zabetian CP. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol. 2016 Oct 1;73(10):1217-1224. PMC5056861.

Flanagan M, Larson EB, Latimer CS, Cholerton B, Crane PK, Montine KS, White LR, Keene CD, Montine TJ. Clinical-pathologic correlations in vascular cognitive impairment and dementia. Biochim Biophys Acta 2016; 1862:945-51. PMC4769968

Hossein-Nezhad A, Fatemi RP, Ahmad R, Peskind ER, Zabetian CP, Hu SC, Shi M, Wahlestedt C, Zhang J, Faghihi MA. Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson’s Disease. J Parkinsons Dis. 2016;6(1):109-17. PMC4927907

Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H, Cairns NJ, Crary JF, Duyckaerts C, Ghetti B, Halliday GM, Ironside JW, Love S, Mackenzie IR, Munoz DG, Murray ME, Nelson PT, Takahashi H, Trojanowski JQ, Ansorge O, Arzberger T, Baborie A, Beach TG, Bieniek KF, Bigio EH, Bodi I, Dugger BN, Feany M, Gelpi E, Gentleman SM, Giaccone G, Hatanpaa KJ, Heale R, Hof PR, Hofer M, Hortobágyi T, Jellinger K, Jicha GA, Ince P, Kofler J, Kövari E, Kril JJ, Mann DM, Matej R, McKee AC, McLean C, Milenkovic I, Montine TJ, Murayama S, Lee EB, Rahimi J, Rodriguez RD, Rozemüller A, Schneider JA, Schultz C, Seeley W, Seilhean D, Smith C, Tagliavini F, Takao M, Thal DR, Toledo JB, Tolnay M, Troncoso JC, Vinters HV, Weis S, Wharton SB, White CL 3rd, Wisniewski T, Woulfe JM, Yamada M, Dickson DW. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016 Jan;131(1):87-102. PMC4879001.

Mata IF, Davis MY, Lopez AN, Dorschner MO, Martinez E, Yearout D, Cholerton BA, Hu SC, Edwards KL, Bird TD, Zabetian CP. The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson’s disease, adds to the complexity of a mutational hotspot. Am J Med Genet B Neuropsychiatr Genet. 2016 Oct;171(7):925-30. PMC5028305

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson’s disease. Mov Disord 2016; 31:95-102. PMC4724255

Moelter ST, Weintraub D, Mace L, Cary M, Sullo E, Xie SX, Karlawish J. Research consent capacity varies with executive function and memory in Parkinson’s disease. Mov Disord. 2016 Mar;31(3):414-7. PMC5213840.

Shi M, Kovac A, Korff A, Cook TJ, Ginghina C, Bullock KM, Yang L, Stewart T, Zheng D, Aro P, Atik A, Kerr KF, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Montine TJ, Banks WA, Zhang J. CNS tau efflux via exosomes is likely increased in Parkinson’s disease but not in Alzheimer’s disease. Alzheimers Dement. 2016 Nov;12(11):1125-1131. PMC5107127.

Smulders K, Dale ML, Carlson-Kuhta P, Nutt JG, Horak FB. Pharmacological treatment in Parkinson’s disease: Effects on gait. Parkinsonism Relat Disord. 2016 Oct;31:3-13. PMC5048566.

Toledo JB, Gopal P, Raible K, Irwin DJ, Brettschneider J, Sedor S, Waits K, Boluda S, Grossman M, Van Deerlin VM, Lee EB, Arnold SE, Duda JE, Hurtig H, Lee VM, Adler CH, Beach TG, Trojanowski JQ. Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology. Acta Neuropathol. 2016 Mar;131(3):393-409. PMC4754135.

Wang L, Maldonado L, Beecham GW, Martin ER, Evatt ML, Ritchie JC, Haines JL, Zabetian CP, Payami H, Pericak-Vance MA, Vance JM, Scott WK. DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient. Neurol Genet. 2016 Apr 12;2(3):e72. PMC4830205.

White LR, Edland SD, Hemmy LS, Montine KS, Zarow C, Sonnen JA, Uyehara-Lock JH, Gelber RP, Ross GW, Petrovitch H, Masaki KH, Lim KO, Launer LJ, Montine TJ. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology. 2016 Mar 15;86(11):1000-8. PMC4799714.

Park JH, Mancini M, Carlson-Kuhta P, Nutt JG, Horak FB. Quantifying effects of age on balance and gait with inertial sensors in community-dwelling healthy adults. Exp Gerontol. 2016 Dec 1;85:48-58. PMC5101181.

Askren MK, McAllister-Day TK, Koh N, Mestre Z, Dines JN, Korman BA, Melhorn SJ, Peterson DJ, Peverill M, Qin X, Rane SD, Reilly MA, Reiter MA, Sambrook KA, Woelfer KA, Grabowski TJ, Madhyastha TM. Using Make for Reproducible and Parallel Neuroimaging Workflow and Quality-Assurance. Front Neuroinform 2016; 10:2. PMC4735413

Bekris LM, Millard S, Tsuang DW, Peskind ER, Yu CE, Montine TJ, Zhang J, Zabetian CP, Leverenz JB. Cerebrospinal Fluid Aβ42 Levels and APP Processing Pathway Genes in Parkinson’s Disease. Mov Disord. 2015 Jun;30(7):936-44. PMC4478197.

Cornejo MR, Torres L, Mata I, Mazzetti PE, Rivas D, Cosentino C, Inca-Martinez M,Cuba JM, Zabetian CP, Leverenz JB. A Peruvian family with a novel PARK2 mutation: Clinical and Pathological Characteristics. Parkinsonism Relat Disord 2015; 21:444-8. PMC4527610

Costa-Mallen P, Zabetian CP, Agarwal P, Hu SC, Yearout D, Samii A, Leverenz JB, Roberts JW, Checkoway H. Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk. Parkinsonism Relat Disord 2015; 21:1087-92. PMC4554997

Darvas M, Palmiter RD. Specific contributions of N-methyl-d-aspartate receptors in the dorsal striatum to cognitive flexibility. Neuroscience. 2015 Jan 22;284:934-42. PMC4267923.

Kelly VE, Johnson CO, McGough EL, Shumway-Cook A, Horak FB, Chung KA, Espay AJ, Revilla FJ, Devoto J, Wood-Siverio C, Factor SA, Cholerton B, Edwards KL, Peterson AL, Quinn JF, Montine TJ, Zabetian CP, Leverenz JB. Association of cognitive domains with postural instability/gait disturbance in Parkinson’s disease. Parkinsonism Relat Disord 2015; 21:692-7. PMC4524498

Lin X, Shi M, Masilamoni JG, Dator R, Movius J, Aro P, Smith Y, Zhang J. Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery. Biochim Biophys Acta 2015; 1854:779-87.PMC4760626

*Liu C, *Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P; Parkinson Study Group DATATOP Investigators, Zhang J. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson’s disease. Parkinsonism Relat Disord. 2015 Mar;21(3):271-6. PMC4603566. *co-first authors

Madhyastha TM, Askren MK, Boord P, Grabowski TJ. Dynamic connectivity at rest predicts attention task performance. Brain Connect 2015; 5:45-59. PMC4313397

Madhyastha T, Askren M, Boord P, Zhang J, Leverenz JB, Grabowski T. Cerebral Perfusion and Cortical Thickness Indicate Cortical Involvement in Mild Parkinson’s disease. Mov Disord. 2015 Dec;30(14):1893-900. PMC4567553.

Madhyastha TM, Askren MK, Zhang J, Leverenz JB, Montine TJ, Grabowski TJ. Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson’s disease. Brain 2015; 138:2672-86. PMC4643623

Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP. The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease. Mol Neurodegener 2015; 10:50. PMC4581468

Melief EJ, Cudaback E, Jorstad NL, Sherfield E, Postupna N, Wilson A, Darvas M, Montine KS, Keene CD, Montine TJ. Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer’s disease. J Neurosci Res 2015; 93:1413-22. PMC4504797

Mischley LK, Leverenz JB, Lau RC, Polissar NL, Neradilek MB, Samii A, Standish LJ. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson’s disease. Mov Disord 2015; 30:1696-701. PMC4609266

Montine TJ and Montine KS. Precision medicine: Clarity for the clinical and biological complexity of Alzheimer’s and Parkinson’s diseases. J Exp Med 2015; 212:601-5. PMC4419342

Morgan RG, Gibbs JT, Melief EJ, Postupna NO, Sherfield EE, Wilson A, Keene CD, Montine TJ, Palmiter RD, Darvas M. Relative contributions of severe dopaminergic neuron ablation and dopamine depletion to cognitive impairment. Exp Neurol 2015; 271:205-14. PMC4586402

Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB. Diagnosis of Parkinson’s disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol 2015; 14:1002-9. PMC4575273

Penzo MA, Robert V, Tucciarone J, De Bundel D, Wang M, Van Aelst L, Darvas M, Parada LF, Palmiter RD, He M, Huang ZJ, Li B. The paraventricular thalamus controls a central amygdala fear circuit. Nature 2015; 519:455-9. PMC4376633

Postupna N, Keene CD, Crane PK, Gonzalez-Cuyar LF, Sonnen JA, Hewitt J, Rice S, Howard K, Montine KS, Larson EB, Montine TJ. Cerebral Cortical Aβ42 and PHF-τ in 325 Consecutive Brain Autopsies Stratified by Diagnosis, Location, and APOE. J Neuropathol Exp Neurol. 2015 Feb;74(2):100-9. PMC4294957.

Shang J, Zrazhevskiy P, Postupna N, Keene CD, Montine TJ, Gao X. Multiplexed In-cell Immunoassay for Same-sample Protein Expression Profiling. Sci Rep 2015; 5:13651. PMC4556981

Shi M, Movius J, Dator R, Aro P, Zhou Y, Pan C, Lin X, Stewart T, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Zhang J. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Mol Cell Proteomics 2015; 14:544-55. PMC4349976

2015 Trojanowski J, Van Deerlin V, Quinn J, Chung K, Peterson A, Factor S, Wood- Siverio C, Goldman J, Stebbins G, Bernard B, Ritz B, Rausch R, Espay A, Revilla F, Devoto J, Rosenthal L, Dawson T, Albert M, Mata IF, Hu S, Montine KS, Johnson C, Montine TJ, Edwards K, Zhang J, Zabetian CP. Cognitive Profile of LRRK2-related Parkinson’s Disease. Mov Disord 2015; 30:728-33. PMC4397146

Stewart T, Sossi V, Aasly JO, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl A, Wang Y, Ginghina C, Liu C, Cain KC, Auinger P, Kang U, Jensen P, Shi M, Zhang J. Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity. Acta Neuropathol Commun. 2015 Jan 31;3(1):7.

Swanson CR, Li K, Unger TL, Gallagher MD, Van Deerlin VM, Agarwal P, Leverenz J, Roberts J, Samii A, Gross RG, Hurtig H, Rick J, Weintraub D, Trojanowski JQ, Zabetian C, Chen-Plotkin AS. Lower plasma Apolipoprotein A1 levels are found in Parkinson’s disease and associate with apolipoprotein A1 genotype. Mov Disord 2015; 30:805-12. PMC4362847

Wang L, Evatt ML, Maldonado LG, Perry WR, Ritchie JC, Beecham GW, Martin ER, Haines JL, Pericak-Vance MA, Vance JM, Scott WK. Vitamin D from different sources is inversely associated with Parkinson disease. Mov Disord 2015; 30:560-6. PMC4390412

Yang Y, Keene CD, Peskind ER, Galasko DR, Hu SC, Cudaback E, Wilson AM, Li G, Yu CE, Montine KS, Zhang J, Baird GS, Hyman BT, Montine TJ. Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. J Neuropathol Exp Neurol 2015; 74:672-87. PMC4471879

Beecham GW, Dickson DW, Scott WK, Martin ER, Schellenberg G, Nuytemans K,Larson EB, Buxbaum JD, Trojanowski JQ, Van Deerlin VM, Hurtig HI, Mash DC, Beach TG, Troncoso JC, Pletnikova O, Frosch MP, Ghetti B, Foroud TM, Honig LS, MarderK, Vonsattel JP, Goldman SM, Vinters HV, Ross OA, Wszolek ZK, Wang L, DykxhoornDM, Pericak-Vance MA, Montine TJ, Leverenz JB, Dawson TM, Vance JM. PARK10 is amajor locus for sporadic neuropathologically confirmed Parkinson disease. Neurology. 2015 Mar 10;84(10):972-80. PMC4352096.

Burdick DJ, Cholerton B, Watson GS, Siderowf A, Trojanowski JQ, Weintraub D, Ritz B, Rhodes SL, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Srivatsal S, Edwards KL, Montine TJ, Zabetian CP, Leverenz JB. People with Parkinson’s disease and normal MMSE score have a broad range of cognitive performance. Mov Disord. 2014 Sep;29(10):1258-64. PMC4162839.

Chahine LM, Stern MB, Chen-Plotkin A. Blood-based biomarkers for Parkinson’s disease. Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S99-103. PMC4070332

Cholerton BA, Zabetian CP, Wan JY, Montine TJ, Quinn JF, Mata IF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Leverenz JB, Edwards KL. Evaluation of mild cognitive impairment subtypes in Parkinson’s disease. Mov Disord. 2014; 29:756-64. PMC4013249.

Cohen RG, Klein KA, Nomura M, Fleming M, Mancini M, Giladi N, Nutt JG, Horak FB. Inhibition, executive function, and freezing of gait. J Parkinsons Dis. 2014 Jan 1;4(1):111-22. PMC4028962

Darvas M, Henschen CW, Palmiter RD. Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson’s disease. Neurobiol Dis. 2014; 65:112-123. PMC4001780

Darvas M, Wunsch AM, Gibbs JT, Palmiter RD. Dopamine dependency for acquisition and performance of Pavlovian conditioned response. Proc Natl Acad Sci USA. 2014; 111:2764-9. PMC3932907.

Fling BW, Cohen RG, Mancini M, Carpenter SD, Fair DA, Nutt JG, and Horak FB. Functional reorganization of the locomotor network in Parkinson patients with freezing of gait. PLoS One. 2014 Jun 17;9(6):e100291. PMC4061081

Fling BW, Nutt JG, Horak FB. Reply: Does dominant pedunculopontine nucleus exist? Probably not. Brain. 2014 Nov 2. pii: awu317. PMC exempt per NIHMS

Gallardo CM, Darvas M, Oviatt M, Chang CH, Michalik M, Huddy TF, Meyer EE, Shuster SA, Aguayo A, Hill EM, Kiani K, Ikpeazu J, Martinez JS, Purpura M, Smit AN, Patton DF, Mistlberger RE, Palmiter RD, Steele AD. Dopamine receptor 1 neurons in the dorsal striatum regulate food anticipatory circadian activity rhythms in mice. Elife. 2014 Sep 12;3:e03781. PMC4196120.

Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov Disord. 2014; 29:634-50. PMC4049032

Hatano T, Funayama M, Kubo S, Mata IF, Oji Y, Mori A, Zabetian CP, Waldherr SM, Yoshino H, Oyama G, Shimo Y, Fujimoto K, Oshima H, Kunii Y, Yabe H, Mizuno Y, Hattori N. Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson’s disease. Neurobiol Aging. 2014 Nov;35(11):2656.e17-23. PMC4171438.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP. APOE, MAPT, and SNCA Genes and Cognitive Performance in Parkinson Disease. JAMA Neurol. 2014 Nov 1;71(11):1405-12. PMC4227942.

Millard SP, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang D, Yu CE, Peskind ER, Bekris LM. Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects. Neurobiol Aging. 2014; 35:357-64. PMC3859300.

Nuytemans K, Inchausti V, Beecham GW, Wang L, Dickson DW, Trojanowski JQ, Lee VM, Mash DC, Frosch MP, Foroud TM, Honig LS, Montine TJ, Dawson TM, Martin ER, Scott WK, Vance JM. Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson’s disease. Mov Disord. 2014; 29:827-30. PMCID: PMC4022044.

Pan C, Zhou Y, Dator R, Ginghina C, Zhao Y, Movius J, Peskind E, Zabetian CP, Quinn J, Galasko D, Stewart T, Shi M, Zhang J. Targeted discovery and validation of plasma biomarkers of Parkinson’s disease. J Proteome Res. 2014 Nov 7;13(11):4535-45. PMC4224986.

Postupna NO, Keene CD, Latimer C, Sherfield EE, Van Gelder RD, Ojemann JG, Montine TJ, Darvas M. Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer’s disease. Lab Invest. 2014 Oct;94(10):1161-72. PMC4184945.

Shi M, Liu C, Cook TJ, Bullock KM, Zhao Y, Ginghina C, Li Y, Aro P, Dator R, He C, Hipp MJ, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Banks WA, Zhang J. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol. 2014 Nov;128(5):639-50. PMC4201967.

2014 Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J; Parkinson Study Group DATATOP Investigators. Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol. 2014; 184:966-75. PMC3969999.

Stewart T, Sui YT, Gonzalez-CF, Wong DT W, Akin DM, Tumas V, Aasly J, Ashmore E, Aro P, Ginghina C, Korff A, Zabetian CP, Leverenz JB, Shi M, Zhang J. Cheek cell-derived alpha-synuclein and DJ-1 do not differentiate Parkinson’s disease from control. Neurobiol Aging 2014; 35;418-20. PMC3844543

Thomas R, Andrews L, Burman J, Lin, A, Pallanck J. PINK1-Parkin pathway activity is regulated by degradation of PINK1 in the mitochondrial matrix. Plos Genetics. 2014 10:31004279. PMC4038460

Wan JY, Edwards KL, Hutter CM, Mata IF, Samii A, Roberts JW, Agarwal P, Checkoway H, Farin FM, Yearout D, Zabetian CP. Association mapping of the PARK10 region for PD susceptibility genes. Parkinsonism Relat Disord 2014; 20:93-98. PMC3946853

Bekris LM, Lutz F, Montine TJ, Yu CE, Tsuang D, Peskind ER, Leverenz JB. MicroRNA in Alzheimer’s disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers 2013; 18:455-66. PMC3967870

Chahine LM, Qiang JK, Ashbridge E, Minger J, Yearout D, Horn S, Colcher A, Hurtig H, Lee VM, Van Deerlin VM, Leverenz JB, Siderowf A, Trojanowski JQ, Zabetian CP, Chen-Plotkin A. Clinical and biochemical differences in Parkinson’s patients with and without GBA mutations. JAMA Neurol 2013; 70:852-8. PMC3762458

Cholerton B, Larson EB, Baker LD, Craft S, Crane PK, Millard SP, Sonnen JA, Montine TJ. Neuropathologic correlates of cognition in a population-based sample. J Alzheimers Dis 2013; 36:699-709. PMC3737376

Cholerton BA, Zabetian CP, Quinn JF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Edwards KL, Montine TJ, Leverenz JB. Pacific Northwest Udall Center of Excellence Clinical Consortium: Study design and baseline cohort characteristics. J Parkinsons Dis. 2013; 3:205-14. PMC3779428

Dombroski BA, Galasko DR, Mata IF, Zabetian CP, Craig UK, Garruto RM, Oyanagi K, Schellenberg GD. C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis/parkinsonism dementia complex. JAMA Neurol 2013;15:1-4. PMC3771869

Erten-Lyons D, Woltjer R, Kaye J, Mattek N, Dodge HH, Green S, Tran H, Howieson DB, Wild K, Silbert LC. Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 2013; 81:977-83. PMC3888199

Fling BW, Cohen, RG, Mancini, M, Nutt, JG, Fair, DA, and Horak, FB. Asymmetric pedunculopontine network connectivity in parkinsonian patients with freezing of gait. Brain. 2013; 136:2405-18. PMC3722352

Hall TO, Wan JY, Mata IF, Kerr KF, Snapinn KW, Samii A, Roberts JW, Agarwal P, Zabetian CP, Edwards KL Risk prediction for complex diseases: application to Parkinson’s disease. Genet Med 2013;15:361-367. PMC3687522.

Henschen CW, Palmiter RD, Darvas M. Restoration of dopamine signaling to the dorsal striatum is sufficient for aspects of active maternal behavior in female mice. Endocrinology. 2013 Nov;154(11):4316-27. PMC5398593.

Karlawish J, Cary M, Moelter ST, Siderowf A, Sullo E, Xie S, Weintraub D. Cognitive impairment and PD patients’ capacity to consent to research. Neurology 2013; 81:801-7. PMC3908465.

Korff A, Liu C, Ginghina C, Shi M, Zhang J. α-Synuclein in Cerebrospinal Fluid of Alzheimer’s Disease and Mild Cognitive Impairment. J Alzheimer’s Dis. 2013; 36:679-88. PMC3740054.

Korvatska O, Strand NS, Berndt JD, Strovas T, Chen D-H, Leverenz JB, Kiianitsa K, Mata IF, Karakoc E, Greenup JL, Bonkowski E, Chuang J, Moon RT, Eichler EE, Nickerson DA, Zabetian CP, Kraemer BC, Bird TD, Raskind WH. Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). Hum Mol Genet, 2013; 22:3259-68. PMC3723311

Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord 2011; 17:61-64. PMC3071582 Li X, Rose SE, Montine KS, Keene CD, Montine TJ. Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid beta neurotoxicity in vitro. J Neuroimmune Pharmacol 2013; 8 87-93. PMC3700810

Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JB, Kraemer BC. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.Ann Neurol 2013; 74:39-52. PMC3775949

Mata IF, Alvarez V, Ribacoba R, Infante J, Sierra M, Gómez-Garre P, Mir P, Waldherr S, Yearout D, Latin American Research Consortium on the Genetics of Parkinson’s Disease, Zabetian CP. Novel Lrrk2-p.S1761R Mutation is not a common cause of Parkinson’s disease in Spain. Mov Disord. 2013; 28:248 PMC3686294

Mattison HA, Nie H, Gao H, Zhou H, Hong J-S, Zhang J. Suppressed pro-inflammatory response of microglia in CX3CR1 knockout mice. J Neuroimmunol 2013; 257:110-5. PMC3702048

Mattsson N, Insel P, Tosun D, Zhang J, Jack CR Jr, Galasko D, Weiner M; Alzheimer’s Disease Neuroimaging Initiative. Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer’s disease. PLoS One. 2013; 8:e85443. PMC3877372.

Montine KS, Montine TJ. Anatomic and clinical pathology of cognitive impairment and dementia. J Alzheimers Dis. 2013; 33 Suppl 1:S181-4. PMC3686298

Peterson AL, Murchison C, Zabetian C, Leverenz JB, Watson GS, Montine T, Carney N, Bowman GL, Edwards K, Quinn JF. Memory, mood, and Vitamin D in persons with Parkinson’s disease. J Parkinsons Dis. 2013 ; 3:547-55. PMC3966187

Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM-Y, Trojanowski JQ, Yearout DB, Leverenz J, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin AS. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol 2013; 74:119-27. PMC3773265

Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer’s disease. Acta Neuropathol 2013; 126:683-97. PMC3812407

Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, Irwin DJ, Rick J, Schellenberg GD, Watson GS, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Quinn JF, Chung KA, Yearout D, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP. APOE epsilon 4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 2013; 70:223-8. PMC3580799

Wang J, Hoekstra JG, Zuo C, Cook TJ, Zhang J. Biomarkers of Parkinson’s disease: current status and future perspectives. Drug Discov Today 2013; 18:155-62. PMC3557745

Watson GS, Cholerton BA, Gross RG, Weintraub D, Zabetian CP, Trojanowski JQ, Montine TJ, Siderowf A, Leverenz JB. Neuropsychologic assessment in collaborative Parkinson’s disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson’s Disease Research at the University of Pennsylvania and the University of Washington. Alzheimers Dement 2013; 9:609-14. PMC3612566

Wang W, Darvas M, Storey GP, Bamford IJ, Gibbs JT, Palmiter RD, Bamford NS. Acetylcholine encodes long-lasting presynaptic plasticity at glutamatergic synapses in the dorsal striatum after repeated amphetamine exposure. J Neurosci 2013; 33:10405-26. PMC3685836

Zhang J, Mattison HA, Liu C, Ginghina C, Auinger P, McDermott MP, Stewart T, Kang UJ, Parkinson Study Group DATATOP Investigators, Cain KC, Shi M. Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol 2013; 126:671-82. PMC3796193.

Bekris LM, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Montine TJ, Peskind ER, Yu CE. ADAM10 expression and promoter haplotype in Alzheimer’s disease. Neurobiol Aging 2012; 33:2229 e2221-2229. PMC3391324

Bekris LM, Millard S, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Yu CE, Peskind ER. Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet, 2012;159B:874-83. PMC3826266.

Christie D, Shofer J, Millard SP, Li E, Demichele-Sweet MA, Weamer EA, Kamboh MI, Lopez OL, Sweet RA, Tsuang D. Genetic association between APOE*4 and neuropsychiatric symptoms in patients with probable Alzheimer’s disease is dependent on the psychosis phenotype. Behav Brain Funct 2012; 8:62. PMC3549850

Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P, Alzheimer’s Disease Cooperative Study Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012; 69 836-41. PMC3661272

Ho L, Zhao W, Dams-O’Connor K, Tang CY, Gordon W, Peskind ER, Yemul S, Haroutunian V, Pasinetti GM. Elevated plasma MCP-1 concentration following traumatic brain injury as a potential ”predisposition” factor associated with an increased risk for subsequent development of Alzheimer’s disease. J Alzheimers Dis 2012; 31:301-13. PMC3576700

Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 2012; 8:1-13. PMC3266529

Irwin DJ, White M, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VMY, Leverenz JB, Montine TJ, Duda J, Hurtig HI, and Trojanowski JQ. Neuropathologic substrates of Parkinson’s disease dementia. Ann Neurol 2012; 72:587-98. PMC3484250

Lin X, Cook TJ, Zabetian CP, Leverenz JB, Peskind ER, Hu SC, Cain KC, Pan C, Edgar JS, Goodlett DR, Racette BA, Checkoway H, Montine TJ, Shi M, Zhang J. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep. 2012; 2:954. PMC3518819.

Mata IF, Checkoway H, Hutter CM, Samii A, Roberts JW, Kim HM, Agarwal P, Alvarez V, Ribacoba R, Pastor P, Lorenzo-Betancor O, Infante J, Sierra M, Gomez-Garre P, Mir P, Ritz B, Rhodes SL, Colcher A, Van Deerlin V, Chung KA, Quinn JF, Yearout D, Martinez E, Farin FM, Wan JY, Edwards KL, Zabetian CP Common variation in the LRRK2 gene is a risk factor for Parkinson’s disease. Mov Disord 2012; 27:1822-1825. PMC3536918.

Mollenhauer B, Zhang J. Biochemical premotor biomarkers for Parkinson’s disease. Mov Disord 2012; 27:644-650. PMC3428741

Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 2012; 123:1-11. PMC3268003

Montine TJ, Sonnen JA, Montine KS, Crane PK, Larson EB. Adult Changes in Thought Study: Dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics. Curr Alzheimer Res 2012; 9:718-723. PMC3409333

Postupna N, Rose SE, Bird TD, Gonzalez-Cuyar LF, Sonnen JA, Larson EB, Keene CD, Montine TJ. Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults. Brain Pathol 2012; 22:472-484. PMC3295908

Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson PT, Dewar K, Clark LN, Crary JF The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol 2012; 124:693-704. PMC3608475

Shi M, Furay AR, Sossi V, Aasly JO, Armaly J, Wang Y, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Zhang J. DJ-1 and alpha synuclein in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging 2012; 33:836.e5-7. PMC3279603

Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Trojanowski JQ, Schellenberg GD, Yearout D, Huston H, Fritts-Penniman A, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 2012; 79:1944-1950. PMC3484986

Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J. Phosphorylated alpha-synuclein in Parkinson’s disease. Sci Transl Med 2012; 4:121ra120. PMC3302662

Aasly JO, Shi M, Sossi V, Stewart T, Johansen KK, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Kim HM, Leverenz JB, Ginghina C, Armaly J, Edwards KL, Snapinn KW, Stoessl AJ, Zhang J. Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers. Neurology 2012; 78:55-61. PMC3466497

Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, Yu CE. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer’s disease. Neurobiol Aging 2011; 32:556 e513-523. PMC3065534

Beutler LR, Eldred KC, Quintana A, Keene CD, Rose SE, Postupna N, Montine TJ, Palmiter RD. Severely impaired learning and altered neuronal morphology in mice lacking NMDA receptors in medium spiny neurons. PLoS One 2011; 6:e28168. PMC3221701

Darvas M, Fadok JP, Palmiter RD. Requirement of dopamine signaling in the amygdala and striatum for learning and maintenance of a conditioned avoidance response. Learn Mem 2011; 18:136-143. PMC3120097

Darvas M, Palmiter RD. Contributions of striatal dopamine signaling to the modulation of cognitive flexibility. Biol Psychiatry 2011; 69:704-707. PMC3120097

Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP, Leverenz JB, Shi M, Zhang J. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain 2011; 134:e178. PMC3122368

Gonzalez-Cuyar LF, Sonnen JA, Montine KS, Keene CD, Montine TJ. Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment. Curr Neurol Neurosci Rep 2011; 11:455-463. PMC3213691

Guthrie CR, Greenup L, Leverenz JB, Kraemer BC. MSUT2 is a determinant of susceptibility to tau neurotoxicity. Hum Mol Genet 2011; 20:1989-1999. PMC3080609

Jayadev S, Nochlin D, Poorkaj P, Steinbart EJ, Mastrianni JA, Montine TJ, Ghetti B, Schellenberg GD, Bird TD, Leverenz JB. Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol 2011; 69:712-720. PMC3114566

Mata IF, Wilhoite GJ, Yearout D, Bacon JA, Cornejo-Olivas M, Mazzetti P, Marca V, Ortega O, Acosta O, Cosentino C, Torres L, Medina AC, Perez-Pastene C, Diaz-Grez F, Vilarino-Guell C, Venegas P, Miranda M, Trujillo-Godoy O, Layson L, Avello R, Dieguez E, Raggio V, Micheli F, Perandones C, Alvarez V, Segura-Aguilar J, Farrer MJ, Zabetian CP, Ross OA. Lrrk2 p.Q1111H substitution and Parkinson’s disease in Latin America. Parkinsonism Relat Disord 2011; 17:629-631. PMC3167927

Mata IF, Yearout D, Alvarez V, Coto E, de Mena L, Ribacoba R, Lorenzo-Betancor O, Samaranch L, Pastor P, Cervantes S, Infante J, Garcia-Gorostiaga I, Sierra M, Combarros O, Snapinn KW, Edwards KL, Zabetian CP. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson’s disease. Mov Disord 2011; 26:819-823. PMC3082603

McMillan PJ, Kraemer BC, Robinson L, Leverenz JB, Raskind M, Schellenberg G. Truncation of tau at E391 promotes early pathologic changes in transgenic mice. J Neuropathol Exp Neurol 2011; 70:1006-1019. PMC3237612

McMillan PJ, White SS, Franklin A, Greenup JL, Leverenz JB, Raskind MA, Szot P. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson’s disease and Alzheimer’s disease. Brain Res 2011; 1373:240-252. PMC3038670

Milatovic D, Montine TJ, Aschner M. Measurement of isoprostanes as markers of oxidative stress. Methods Mol Biol 2011; 758:195-204. PMC3277600

Montine TJ. Prevalence estimates for latent neurodegenerative disease. Toxicol Pathol 2011; 39:99-102. PMC3062523

Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69:570-580. PMC3117674

Shi M, Sui YT, Peskind ER, Li G, Hwang H, Devic I, Ginghina C, Edgar JS, Pan C, Goodlett DR, Furay AR, Gonzalez-Cuyar LF, Zhang J. Salivary tau species are potential biomarkers of Alzheimer’s disease. J Alzheimers Dis 2011; 27:299-305. PMC3302350

Shi M, Zhang J. CSF alpha-synuclein, tau, and amyloid beta in Parkinson’s disease. Lancet Neurol 2011; 10:681; author’s reply 681-683. PMC exempt per NIHMS

Snapinn KW, Larson EB, Kawakami H, Ujike H, Borenstein AR, Izumi Y, Kaji R, Maruyama H, Mata IF, Morino H, Oda M, Tsuang DW, Yearout D, Edwards KL, Zabetian CP. The UCHL1 S18Y polymorphism and Parkinson’s disease in a Japanese population. Parkinsonism Relat Disord 2011; 17:473-475. PMC3119730

Sonnen JA, Santa Cruz K, Hemmy LS, Woltjer R, Leverenz JB, Montine KS, Jack CR, Kaye J, Lim K, Larson EB, White L, Montine TJ. Ecology of the aging human brain. Arch Neurol 2011; 68:1049-1056. PMC3218566

Wall VZ, Parker JG, Fadok JP, Darvas M, Zweifel L, Palmiter RD. A behavioral genetics approach to understanding D1 receptor involvement in phasic dopamine signaling. Mol Cell Neurosci 2011; 46:21-31. PMC3035386

Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, Goldstein DS, Shi M, Zhang J. Complement 3 and factor h in human cerebrospinal fluid in Parkinson’s disease, Alzheimer’s disease, and multiple-system atrophy. Am J Pathol 2011; 178:1509-1516. PMC3078443

Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010; 23:228-242. PMC3044594

Caudle WM, Bammler TK, Lin Y, Pan S, Zhang J. Using ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease. Expert Rev Neurother 2010; 10:925-942. PMC2913169

Darvas M, Palmiter RD. Restricting dopaminergic signaling to either dorsolateral or medial striatum facilitates cognition. J Neurosci 2010; 30:1158-65. PMC3771669

Fadok JP, Darvas M, Dickerson TM, Palmiter RD. Long-term memory for pavlovian fear conditioning requires dopamine in the nucleus accumbens and basolateral amygdala. PLoS One 2010; 5:e12751. PMC2939886

Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian CP. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact 2010; 187:355-361. PMC3035622

Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 2010; 133:713-726. PMC2842513

Kay DM, Stevens CF, Hamza TH, Montimurro JS, Zabetian CP, Factor SA, Samii A, Griffith A, Roberts JW, Molho ES, Higgins DS, Gancher S, Moses L, Zareparsi S, Poorkaj P, Bird T, Nutt J, Schellenberg GD, Payami H. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 2010; 75:1189-1194. PMC3013490

Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, Galasko DR, Ginghina C, Griffith A, Higgins DS, Kay DM, Kim H, Leverenz JB, Quinn JF, Roberts JW, Samii A, Snapinn KW, Tsuang DW, Yearout D, Zhang J, Payami H, Zabetian CP. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 2010; 67:1350-1356. PMC3010848

Milatovic D, Montine TJ, Zaja-Milatovic S, Madison JL, Bowman AB, Aschner M. Morphometric analysis in neurodegenerative disorders. Curr Protoc Toxicol 2010; Chapter 12:Unit 12 16. PMC2855147

Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J. CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord 2010; 25:2682-2685. PMC2978754

Poorkaj P, Raskind WH, Leverenz JB, Matsushita M, Zabetian CP, Samii A, Kim S, Gazi N, Nutt JG, Wolff J, Yearout D, Greenup JL, Steinbart EJ, Bird TD. A novel X-linked four-repeat tauopathy with Parkinsonism and spasticity. Mov Disord 2010; 25:1409-1417. PMC3123999

2010 Shi M, Huber BR, Zhang J. Biomarkers for cognitive impairment in Parkinson disease. Brain Pathol 2010; 20:660-671. PMC2881485

Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease. Neurosci Lett 2010; 480:78-82. PMC2943649

Silbert LC, Kaye J. Neuroimaging and cognition in Parkinson’s disease dementia. Brain Pathol 2010; 20:646-653. PMC3327506

Snyder LR, Hoggard JC, Montine TJ, Synovec RE. Development and application of a comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometry method for the analysis of L-beta-methylamino-alanine in human tissue. J Chromatogr A 2010; 1217:4639-4647. PMC2901168

Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, Breitner JC, Montine TJ. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 2010; 75:1203-1210. PMC3013492

Sonnen JA, Postupna N, Larson EB, Crane PK, Rose SE, Montine KS, Leverenz JB, Montine TJ. Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol 2010; 20:654-659. PMC2881486

Watson GS, Leverenz JB. Profile of cognitive impairment in Parkinson’s disease. Brain Pathol 2010; 20:640-645. PMC3049172

Leverenz JB, Quinn JF, Zabetian C, Zhang J, Montine KS, Montine TJ. Cognitive impairment and dementia in patients with Parkinson disease. Current topics in medicinal chemistry. 2009;9(10):903-12. PMC2804995.